Limits...
In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe.

Shimizu Y, Temma T, Hara I, Makino A, Kondo N, Ozeki E, Ono M, Saji H - Cancer Sci. (2014)

Bottom Line: In aqueous buffer, MT1-hIC7L fluorescence was suppressed to background levels and increased approximately 35.5-fold in the presence of detergent.In MT1-MMP negative MCF-7 breast adenocarcinoma cells, both MT1-hIC7L and hIC7L showed no obvious fluorescence.In addition, the fluorescence intensity of C6 cells treated with MT1-hIC7L was suppressed by pre-treatment with an MT1-MMP endocytosis inhibitor (P < 0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan; Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan.

Show MeSH

Related in: MedlinePlus

In vivo imaging of MT1-hIC7L. (a,c) Fluorescence images of C6 cell xenografted mice (a) or MCF-7 xenografted mice (c) at 0 h (just after injection), 12, 24 and 48 h after administration of MT1-hIC7L (upper) and hIC7L (lower). Arrows indicate the tumor tissue. (b,d) The C6 tumor (b) or MCF-7 tumor (d) -to-background (T/B) fluorescence intensity ratios obtained from the region of interest of the tumor and background (neck) of mice administered MT1-hIC7L and hIC7L. Data are expressed as T/B ratio (mean ± SD). Comparison of the T/B ratios of MT1-hIC7L- and hIC7L- administered groups was performed with two-way factorial anova followed by the Tukey–Kramer test (*P < 0.05 vs hIC7L).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317866&req=5

fig04: In vivo imaging of MT1-hIC7L. (a,c) Fluorescence images of C6 cell xenografted mice (a) or MCF-7 xenografted mice (c) at 0 h (just after injection), 12, 24 and 48 h after administration of MT1-hIC7L (upper) and hIC7L (lower). Arrows indicate the tumor tissue. (b,d) The C6 tumor (b) or MCF-7 tumor (d) -to-background (T/B) fluorescence intensity ratios obtained from the region of interest of the tumor and background (neck) of mice administered MT1-hIC7L and hIC7L. Data are expressed as T/B ratio (mean ± SD). Comparison of the T/B ratios of MT1-hIC7L- and hIC7L- administered groups was performed with two-way factorial anova followed by the Tukey–Kramer test (*P < 0.05 vs hIC7L).

Mentions: Compared to the hIC7L administered group, in MT1-hIC7L administered mice the fluorescence gradually increased in C6 xenografted tumors, which could be imaged clearly at 24 and 48 h post-administration (Fig. 4a). In addition, the T/B ratios of MT1-hIC7L increased with time and provided higher values than those of hIC7L (Fig. 4c, 3.2 ± 0.3 vs 2.7 ± 0.2 at 24 h, and 3.8 ± 0.3 vs 3.1 ± 0.2 at 48 h). In mice xenografted with MCF-7 cells which express low levels of MT1-MMP, there was no significant difference in the images between the MT1-hIC7L-administered and hIC7L-administered groups throughout the study duration (Fig. 4b). The T/B ratios in the MCF-7 tumors were unchanged regardless of the probe used (Fig. 4d, 2.5 ± 0.3 vs 2.6 ± 0.2 at 24 h, and 2.8 ± 0.4 vs 3.0 ± 0.2 at 48 h).


In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe.

Shimizu Y, Temma T, Hara I, Makino A, Kondo N, Ozeki E, Ono M, Saji H - Cancer Sci. (2014)

In vivo imaging of MT1-hIC7L. (a,c) Fluorescence images of C6 cell xenografted mice (a) or MCF-7 xenografted mice (c) at 0 h (just after injection), 12, 24 and 48 h after administration of MT1-hIC7L (upper) and hIC7L (lower). Arrows indicate the tumor tissue. (b,d) The C6 tumor (b) or MCF-7 tumor (d) -to-background (T/B) fluorescence intensity ratios obtained from the region of interest of the tumor and background (neck) of mice administered MT1-hIC7L and hIC7L. Data are expressed as T/B ratio (mean ± SD). Comparison of the T/B ratios of MT1-hIC7L- and hIC7L- administered groups was performed with two-way factorial anova followed by the Tukey–Kramer test (*P < 0.05 vs hIC7L).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317866&req=5

fig04: In vivo imaging of MT1-hIC7L. (a,c) Fluorescence images of C6 cell xenografted mice (a) or MCF-7 xenografted mice (c) at 0 h (just after injection), 12, 24 and 48 h after administration of MT1-hIC7L (upper) and hIC7L (lower). Arrows indicate the tumor tissue. (b,d) The C6 tumor (b) or MCF-7 tumor (d) -to-background (T/B) fluorescence intensity ratios obtained from the region of interest of the tumor and background (neck) of mice administered MT1-hIC7L and hIC7L. Data are expressed as T/B ratio (mean ± SD). Comparison of the T/B ratios of MT1-hIC7L- and hIC7L- administered groups was performed with two-way factorial anova followed by the Tukey–Kramer test (*P < 0.05 vs hIC7L).
Mentions: Compared to the hIC7L administered group, in MT1-hIC7L administered mice the fluorescence gradually increased in C6 xenografted tumors, which could be imaged clearly at 24 and 48 h post-administration (Fig. 4a). In addition, the T/B ratios of MT1-hIC7L increased with time and provided higher values than those of hIC7L (Fig. 4c, 3.2 ± 0.3 vs 2.7 ± 0.2 at 24 h, and 3.8 ± 0.3 vs 3.1 ± 0.2 at 48 h). In mice xenografted with MCF-7 cells which express low levels of MT1-MMP, there was no significant difference in the images between the MT1-hIC7L-administered and hIC7L-administered groups throughout the study duration (Fig. 4b). The T/B ratios in the MCF-7 tumors were unchanged regardless of the probe used (Fig. 4d, 2.5 ± 0.3 vs 2.6 ± 0.2 at 24 h, and 2.8 ± 0.4 vs 3.0 ± 0.2 at 48 h).

Bottom Line: In aqueous buffer, MT1-hIC7L fluorescence was suppressed to background levels and increased approximately 35.5-fold in the presence of detergent.In MT1-MMP negative MCF-7 breast adenocarcinoma cells, both MT1-hIC7L and hIC7L showed no obvious fluorescence.In addition, the fluorescence intensity of C6 cells treated with MT1-hIC7L was suppressed by pre-treatment with an MT1-MMP endocytosis inhibitor (P < 0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan; Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan.

Show MeSH
Related in: MedlinePlus